Investigation on Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

Registration

Registration

NCT03095807

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE1

Masking

QUADRUPLE

Status

COMPLETED

Enrollment

34

Start

2017-03-20

Primary completion

2017-08-31

Lead sponsor

Novo Nordisk A/S

Conditions

Metabolism and Nutrition Disorder; Obesity

Interventions

DRUG:NNC9204-1706 A; DRUG:Placebo

Results posted

FALSE

Individual participant data sharing

YES

Secondary identifiers

OTHER:U1111-1177-7821

Registered primary outcomes

• Number of treatment-emergent adverse events (TEAEs) [From the time of dosing (Day 1) and until completion of the post-treatment follow-up visit (Days 10-13)]